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scale. Direct medical costs are divided into outpatient and
hospital costs. Outpatient costs (medical visits, medica-
tion, additional tests, physiotherapy sessions) are to be
assessed using French public prices and Social Security
tariffs. Hospital costs are to be assessed using the PMSI
database. Indirect costs are to be assessed in terms of 
the number and duration of sick-leaves. Costs are to be
assessed from the perspectives of society, patient and
Social Security. The comparability of the 2 patient groups
are to be statistically analysed before comparing results.
CONCLUSION: Given the public-health problem caused
by epidemic infantile bronchiolitis each year in France,
the results of this pragmatic medicoeconomic study will
aid public policy makers and practitioners in determin-
ing the most cost-effective Health care management
strategies.
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OBJECTIVE: To show that indirect intervention costs
can be crucial for the results of large-scale prevention pro-
grams. METHODS: We estimated the indirect costs of the
Dutch meningococcal serogroup C conjugate immuniza-
tion program of all persons aged 14 months to 18 years
that ran from June 2002 until January 2003. Using the
friction cost method, we measured the indirect interven-
tion costs caused by additional health visits due to 
the catch-up immunization program and side effects of
immunization as well as the indirect savings due to
averted cases of meningococcal disease and its complica-
tions. For valuing the work-loss of parents accompany-
ing younger children (less than 15 years) we used the
average labor costs per employed parent that was com-
puted by weighting the age- and sex speciﬁc labor costs
of employees with the age- and sex speciﬁc probabilities
of being a parent. For valuing the work-loss of persons
aged 15 years or older, we used the age- and sex-speciﬁc
labor costs per capita. RESULTS: The immunization
program caused indirect intervention costs of €17.14
million. As the indirect savings due to prevented cases of
meningococcal disease were only €0.75 million, the net
indirect costs were €16.39 million. Including the indirect
costs increases the cost-effectiveness ratio of the immu-
nization program from about €13,200 per life year gained
to about €17,700 per life year gained. These results are
sensitive to the work-time loss per vaccination, the way
children were called in for vaccination, i.e. whether by
birth-cohort or by ZIP-code, and the approach for indi-
rect cost measurement. CONCLUSIONS: Indirect inter-
vention costs can be substantial and should always be
measured. Failing to do so cannot only lead to mislead-
ing results but also to higher than necessary indirect costs
as the decision maker might not take them into account
when planning the program setup.
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OBJECTIVE: While Type 1 Diabetes only affects 5–10%
of the 16 million people with diabetes, it accounts for
about 30% of the total costs. The primary purpose of this
presentation is to review the literature and identify cost-
effective treatments for Type I Diabetes. METHOD: A
search was conducted using Medline and other interna-
tional publications and resources. Articles were retrieved
and reviewed with results synthesized and summarized by
the cost effectiveness of the intervention or treatment
method. RESULTS: Studies on the cost-effectiveness of
treatment for Type 1 Diabetes proved difﬁcult to locate.
Economic information regarding treatment varied greatly
across studies, but generally demonstrated a cost beneﬁt.
For interventions of diabetic retinopathy, studies using
simulated populations showed a cost-savings for panreti-
nal photocoagulation for proliferative diabetic retinopa-
thy and focal photocoagulation for macular edema. A
similar cost-saving was found in pre-conception care with
a cost beneﬁt ratio of the care program being 5.19,
meaning for every $1 spent on the program, there would
be a net savings of $5.19. While the rate of costs or
savings were varied, interventions for diabetic nephropa-
thy and glycemic control were clearly cost effective. Two
interventions assessed did not demonstrate cost-
effectiveness: 1) the self-management training interven-
tion which showed only potential cost-effective results,
and 2) the self-monitoring of blood glucose (SMBG)
which displayed unclear results. CONCLUSION: This
review shows that most of the available studies on cost-
effectiveness of Type 1 Diabetes deal with interventions
geared to prevent or arrest the progression of complica-
tions. The most accessible ones are studies on diabetic
retinopathy and nephropathy. Studies that address cost-
effectiveness of self-management and SMBG are difﬁcult
to ﬁnd. For a chronic disease such as Type 1 Diabetes,
non-empirical study data is more common, and the source
of cost-effectiveness data (for modeling, etc.) has also
been derived mostly from non-empirical sources.
